199 related articles for article (PubMed ID: 38319963)
1. DNA hypomethylation ameliorates erosive inflammatory arthritis by modulating interferon regulatory factor-8.
Swarnkar G; Semenkovich NP; Arra M; Mims DK; Naqvi SK; Peterson T; Mbalaviele G; Wu CL; Abu-Amer Y
Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2310264121. PubMed ID: 38319963
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8.
Guo C; Pei L; Xiao X; Wei Q; Chen JK; Ding HF; Huang S; Fan G; Shi H; Dong Z
Kidney Int; 2017 Nov; 92(5):1194-1205. PubMed ID: 28709638
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae.
Yamashita M; Toyota M; Suzuki H; Nojima M; Yamamoto E; Kamimae S; Watanabe Y; Kai M; Akashi H; Maruyama R; Sasaki Y; Yamano H; Sugai T; Shinomura Y; Imai K; Tokino T; Itoh F
Cancer Sci; 2010 Jul; 101(7):1708-16. PubMed ID: 20507321
[TBL] [Abstract][Full Text] [Related]
4. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
5. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
6. Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice.
Zheng Q; Xu Y; Liu Y; Zhang B; Li X; Guo F; Zhao Y
J Mol Med (Berl); 2009 Dec; 87(12):1191-205. PubMed ID: 19841877
[TBL] [Abstract][Full Text] [Related]
7. Decitabine and 5-azacitidine both alleviate LPS induced ARDS through anti-inflammatory/antioxidant activity and protection of glycocalyx and inhibition of MAPK pathways in mice.
Huang X; Kong G; Li Y; Zhu W; Xu H; Zhang X; Li J; Wang L; Zhang Z; Wu Y; Liu X; Wang X
Biomed Pharmacother; 2016 Dec; 84():447-453. PubMed ID: 27685787
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
Tshuikina M; Jernberg-Wiklund H; Nilsson K; Oberg F
Exp Hematol; 2008 Dec; 36(12):1673-1681. PubMed ID: 18922617
[TBL] [Abstract][Full Text] [Related]
9. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.
Si J; Boumber YA; Shu J; Qin T; Ahmed S; He R; Jelinek J; Issa JP
Cancer Res; 2010 Sep; 70(17):6968-77. PubMed ID: 20713525
[TBL] [Abstract][Full Text] [Related]
10. Genomic impact of transient low-dose decitabine treatment on primary AML cells.
Klco JM; Spencer DH; Lamprecht TL; Sarkaria SM; Wylie T; Magrini V; Hundal J; Walker J; Varghese N; Erdmann-Gilmore P; Lichti CF; Meyer MR; Townsend RR; Wilson RK; Mardis ER; Ley TJ
Blood; 2013 Feb; 121(9):1633-43. PubMed ID: 23297133
[TBL] [Abstract][Full Text] [Related]
11. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
13. SPAG6-silencing enhances decitabine-induced apoptosis and demethylation of PTEN in SKM-1 cells and in a xenograft mouse model.
Luo J; Mu J; Zhang M; Zhao B; Liu L
Leuk Lymphoma; 2021 Sep; 62(9):2242-2252. PubMed ID: 33843428
[TBL] [Abstract][Full Text] [Related]
14. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
You L; Han Q; Zhu L; Zhu Y; Bao C; Yang C; Lei W; Qian W
Front Immunol; 2020; 11():1787. PubMed ID: 32973749
[TBL] [Abstract][Full Text] [Related]
15. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
16. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation inhibitor, decitabine, promotes MGC803 gastric cancer cell migration and invasion via the upregulation of NEDD4‑1.
Li D; Xu CY; Cui RJ; Tang JB; Sun H; Yang ZK; Bu JY; Lin P; Huang N; Du YD; Yu XG
Mol Med Rep; 2015 Dec; 12(6):8201-8. PubMed ID: 26458406
[TBL] [Abstract][Full Text] [Related]
18. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
Wang LX; Mei ZY; Zhou JH; Yao YS; Li YH; Xu YH; Li JX; Gao XN; Zhou MH; Jiang MM; Gao L; Ding Y; Lu XC; Shi JL; Luo XF; Wang J; Wang LL; Qu C; Bai XF; Yu L
PLoS One; 2013; 8(5):e62924. PubMed ID: 23671644
[TBL] [Abstract][Full Text] [Related]
19. Decitabine assists umbilical cord-derived mesenchymal stem cells in improving glucose homeostasis by modulating macrophage polarization in type 2 diabetic mice.
Gao J; Cheng Y; Hao H; Yin Y; Xue J; Zhang Q; Li L; Liu J; Xie Z; Yu S; Li B; Han W; Mu Y
Stem Cell Res Ther; 2019 Aug; 10(1):259. PubMed ID: 31426846
[TBL] [Abstract][Full Text] [Related]
20. Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents.
Malkaram SA; Shatnawi A; Fan J; Carraway H; Denvir J; Primerano DA; Abd Elmageed ZY; Fandy TE
Cancer Control; 2022; 29():10732748221074051. PubMed ID: 35067084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
